Article Information
History
- October 14, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Rebecca A. DeStefanis*,1,
- Autumn M. Olson*,1,
- Alyssa K. DeZeeuw1,
- Amani A. Gillette2,
- Gioia C. Sha1,
- Katherine A. Johnson1,
- Jeremy D. Kratz1,3,
- Cheri A. Pasch3,
- Linda Clipson4,
- Melissa C. Skala2,3,5 and
- Dustin A. Deming1,3,4,†
- 1Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin–Madison, Madison, WI
- 2Department of Biomedical Engineering, University of Wisconsin–Madison, Madison, WI
- 3University of Wisconsin Carbone Cancer Center, Madison, WI
- 4McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin– Madison, Madison, WI
- 5Morgridge Institute for Research, Madison, WI
- ↵†Corresponding Author:
Dustin A. Deming MD, 1111 Highland Ave, 6507 WIMR2, Madison, WI 53705, ddeming{at}medicine.wisc.edu
↵* denotes equally contributing authors.
Posted October 14, 2021.
Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity
